Literature DB >> 8839558

The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society.

N E Fleshner1, H W Herr, A K Stewart, G P Murphy, C Mettlin, H R Menck.   

Abstract

BACKGROUND: Previous Commission on Cancer Data from the National Cancer Data Base (NCDB) have examined time trends in stage of disease, treatment patterns, and survival for selected cancers. The most current (1993) data relating to patients with bladder carcinoma are described here.
METHODS: Five calls for data have yielded a total of 3,700,000 cases for the years 1985 through 1993, including 447,679 cases for 1988 and 608,593 cases for 1993, from hospital cancer registries across the U.S. Data were received on 18,053 bladder carcinoma cases in 1988 and 22,606 cases in 1993.
RESULTS: Interesting trends are 1) younger patients (49 years of age and younger) present with earlier stages of disease than do older patients; 2) women are slightly more likely to be diagnosed with later stages (II, III, and IV) of bladder carcinoma than men; 3) African Americans are less likely to be diagnosed with Stage 0 or Stage I disease than either Hispanic or non-Hispanic whites; and 4) National Cancer Institute designated centers treat more patients with advanced disease than do other types of hospitals.
CONCLUSIONS: The NCDB data are important for analyzing what cancer treatments and outcomes are used and occurring in the country. The data suggest that African Americans are diagnosed at later stages of disease progression. The relative survival rates among African Americans are lower than among Hispanics or non-Hispanic whites. Also, the decreasing utility of adjuvant chemotherapy is being recognized.

Entities:  

Mesh:

Year:  1996        PMID: 8839558     DOI: 10.1002/(sici)1097-0142(19961001)78:7<1505::aid-cncr19>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  33 in total

1.  Is there a gender effect in bladder cancer? A population-based study of practice and outcomes.

Authors:  Francis Michael Patafio; D Robert Siemens; Xuejiao Wei; Christopher M Booth
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

2.  Sex disparities in cancer mortality and survival.

Authors:  Michael B Cook; Katherine A McGlynn; Susan S Devesa; Neal D Freedman; William F Anderson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-12       Impact factor: 4.254

3.  Infiltration related miRNAs in bladder urothelial carcinoma.

Authors:  Peng Xie; Feng Xu; Wen Cheng; Jianping Gao; Zhengyu Zhang; Jingping Ge; Zhifeng Wei; Xiaofeng Xu; Youhuang Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-08-11

4.  Geographic Variation in Cystoscopy Rates for Suspected Bladder Cancer between Female and Male Medicare Beneficiaries.

Authors:  David S Han; Weiping Zhou; John D Seigne; Kristine E Lynch; Florian R Schroeck
Journal:  Urology       Date:  2018-08-20       Impact factor: 2.649

Review 5.  Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition.

Authors:  Arlene Siefker-Radtke; Brendan Curti
Journal:  Nat Rev Urol       Date:  2017-12-05       Impact factor: 14.432

6.  Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.

Authors:  Rafael Nunez-Nateras; Erik P Castle; Cheryl A Protheroe; Melissa L Stanton; Tolgay I Ocal; Erin N Ferrigni; Sergei I Ochkur; Elizabeth A Jacobsen; Yue-Xian Hou; Paul E Andrews; Thomas V Colby; Nancy A Lee; James J Lee
Journal:  Urol Oncol       Date:  2013-09-18       Impact factor: 3.498

7.  XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIβ mRNA stability.

Authors:  Yonghui Yu; Honglei Jin; Jiheng Xu; Jiayan Gu; Xin Li; Qipeng Xie; Haishan Huang; Jingxia Li; Zhongxian Tian; Guosong Jiang; Caiyi Chen; Feng He; Xue-Ru Wu; Chuanshu Huang
Journal:  Int J Cancer       Date:  2017-12-28       Impact factor: 7.396

8.  Gender-specific survival following radical cystectomy for pT4 bladder cancer.

Authors:  Dharam Kaushik; Igor Frank; Manuel S Eisenberg; John C Cheville; Robert Tarrell; Prabin Thapa; R Houston Thompson; Stephen A Boorjian
Journal:  World J Urol       Date:  2013-12-21       Impact factor: 4.226

9.  Profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases proteins in bladder urothelial carcinoma.

Authors:  Cheng-Keng Chuang; See-Tong Pang; Tai-Jung Chuang; Shuen-Kuei Liao
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

10.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Authors:  Christophe Massard; Michael S Gordon; Sunil Sharma; Saeed Rafii; Zev A Wainberg; Jason Luke; Tyler J Curiel; Gerardo Colon-Otero; Omid Hamid; Rachel E Sanborn; Peter H O'Donnell; Alexandra Drakaki; Winston Tan; John F Kurland; Marlon C Rebelatto; Xiaoping Jin; John A Blake-Haskins; Ashok Gupta; Neil H Segal
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.